Details of the Drug

General Information of Drug (ID: DMXF9DM)

Drug Name
OXB-102
Synonyms AXO-Lenti-PD
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1/2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D72UDH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatic-L-amino-acid decarboxylase (DDC) TTN451K DDC_HUMAN Not Available [2]
GTP cyclohydrolase-I (GCH1) TTLSWP6 GCH1_HUMAN Not Available [2]
Tyrosine 3-monooxygenase (TH) TTUHP71 TY3H_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine 3-monooxygenase (TH) DTT TH 9.10E-04 -2.73 -1.55
Aromatic-L-amino-acid decarboxylase (DDC) DTT DDC 7.84E-03 -1.49 -1.01
GTP cyclohydrolase-I (GCH1) DTT GCH1 3.38E-02 -1.59 -1.53
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03720418) Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Oxford BioMedica.